Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Тактика ведения больного метастатическим колоректальным раком с изолированными метастазами в печень
Тактика ведения больного метастатическим колоректальным раком с изолированными метастазами в печень
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976–82.
2. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007; 25 (18 suppl.): 2s.
3. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26 (suppl.): abstr 4000.
4. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (suppl.): abstr 2.
5. Bismuth H, Adam R, Lеvi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–20.
6. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644–57.
7. Falcone A, Ricci S, Brunetti I et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13): 1670–6.
8. Abad A, Antоn A, Massuti B et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. J Clin Oncol 2005 ASCO Annual Meeting Proceedings2005; 23 (16S): abstr. 3618.
9. Bouganim N, Kavan P, Eid M et al. Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol 2009; 27 (suppl.): abstr e15027.
10. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939–45.
11. Labianca R, Floriani I, Cortesi E et al. Italian Group for the Study of Digestive Tract Can. Alternating versus continuous «FOLFIRI» in advanced colorectal cancer (ACC): A randomized «GISCAD» trial. J Clin Oncol 2006; 24 (18 suppl.): 3505.
12. Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (mCRC): A GERCOR study. J Clin Oncol 2007; 25 (18 suppl.): 4013.
13. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25 (18S; Suppl.): 4028.
2. Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007; 25 (18 suppl.): 2s.
3. Bokemeyer C, Bondarenko I, Hartmann JT et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26 (suppl.): abstr 4000.
4. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (suppl.): abstr 2.
5. Bismuth H, Adam R, Lеvi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–20.
6. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644–57.
7. Falcone A, Ricci S, Brunetti I et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13): 1670–6.
8. Abad A, Antоn A, Massuti B et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRC) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. J Clin Oncol 2005 ASCO Annual Meeting Proceedings2005; 23 (16S): abstr. 3618.
9. Bouganim N, Kavan P, Eid M et al. Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol 2009; 27 (suppl.): abstr e15027.
10. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939–45.
11. Labianca R, Floriani I, Cortesi E et al. Italian Group for the Study of Digestive Tract Can. Alternating versus continuous «FOLFIRI» in advanced colorectal cancer (ACC): A randomized «GISCAD» trial. J Clin Oncol 2006; 24 (18 suppl.): 3505.
12. Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (mCRC): A GERCOR study. J Clin Oncol 2007; 25 (18 suppl.): 4013.
13. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25 (18S; Suppl.): 4028.
Авторы
А.А.Трякин
Отделение клинической фармакологии и химиотерапии РОНЦ им. Н.Н.Блохина РАМН, Москва
Отделение клинической фармакологии и химиотерапии РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.